ArticleCurrent microbiology2025
The Role of Talaromyces Marneffei Binding To CD86 in the CD86-CTLA4 Regulatory Pathway.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Talaromyces marneffei (TM), an opportunistic pathogenic fungus, binds to CD86, which acts as a co-stimulatory molecule for CTLA4. CD86 activates CTLA4, which transmits inhibitory signals, yet its role in TM immune responses remains unclear. In this study, we investigated how the binding of TM to CD86 modulates the CD86-CTLA4 regulatory pathway. To establish the co-culture system of THP-1/THP-1-CD86-EGFP, TM, and Jurkat, Jurkat cells were first transfected with lentivirus to generate the target cell lines. The interactions among TM, CD86, and CTLA4 within this system were then investigated using confocal fluorescence microscopy. To evaluate changes in the expression levels of target factors, RT-qPCR and Western blotting were performed. Potential downregulated pathways were further identified through RNA sequencing (RNA-Seq) analysis. Additionally, the functional role of CTLA4 in the co-culture system was assessed by bactericidal assays. In the co-culture system, THP-1 macrophages engulfed TM, which bound to CD86 and formed immature phagosomes that subsequently escaped. Escaped TM interacted with Jurkat cells via CD86, activating CTLA4. Transcriptional levels of CD86 and CTLA4 initially increased and then decreased in the TM(+) vs. TM(-) comparison. After 24 h, OE showed significant differences in CD86 and CTLA4 (transcriptional and translational levels) vs. CON and NC, along with differences in IFN-γ, IL-5, and IL-13. At 48 h, CD86 and CTLA4 expression varied with THP-1/CD86-EGFP presence. RNA-seq showed TM proliferation and differentiation downregulated PI3K-Akt and T cell receptor pathways. The fungal killing assay indicated that CTLA4 may facilitate TM in evading immune-mediated damage. TM regulates the CD86-CTLA4 immune regulatory pathway by binding to the CD86 protein, thereby evading the immune killing of macrophages.
Indexed as
Identifiers
41460255What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.